The capital-intensive nature of pharmaceutical drug research and development (R&D) activities and the need to hasten the drug development timelines has resulted in an increase in the outsourcing to clinical dose companies for manufacturing.
Recommended Buyer's Guides
Small to mid-size pharmaceutical companies may especially lack the technical expertise or infrastructure required to manufacture clinical doses in the required quantities and reference standards. Clinical dose companies in contract manufacturing can supply the required quantities of clinical doses and expedite clinical trials.
Find the leading clinical dose companies in contract manufacturing
Pharmaceutical Technology has listed the top clinical dose companies in contract manufacturing based on our intel, insights and decades-long experience in the sector. The list includes providers of various products and services including, but not limited to:
- Pilot batch manufacturing
- Laboratory testing for stability
- Quality control and analysis services
- Medical expert engagement and communication, and
- Commercialisation strategies
The information contained within the download document is designed for pharmaceutical executives, product managers, drug development coordinators, and any other individual involved in clinical dose contract manufacturing.
The download contains detailed information on the providers and their services and solutions, alongside contact details to aid your purchasing or hiring decision.
See Also:
Importance of clinical dose manufacturing in drug development
Clinical dose manufacturing helps in expediting the process of drug development, while the final formulations are still being developed. Contract manufacturers of clinical doses ensure the production of a drug in a controlled environment and record data during the manufacturing process.
Some specialised clinical dose companies also provide services related to packaging, cold chain management, and logistics that support various stages of drug development such as animal studies, toxicity studies, and Phase I research. Pharmaceutical companies should partner with dose providers that use the latest technologies such as nano-particle technology to gain a competitive advantage.